Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth

Pediatr Dermatol. 2016 Sep;33(5):536-42. doi: 10.1111/pde.12946. Epub 2016 Jul 28.

Abstract

Background: Dysregulation of the mammalian target of rapamycin pathway is the underlying pathogenic mechanism in tuberous sclerosis complex (TSC). Other syndromes caused by genetic alterations in this pathway frequently manifest as vascular anomalies or asymmetric overgrowth. Rarely, these features have been documented in TSC.

Objective: To collate cases of TSC with vascular anomaly or overgrowth that have been published and to assemble additional recent cases, as this finding has been underreported.

Methods: TSC cases from three pediatric dermatology referral centers on two continents were reviewed to identify individuals noted to have hemihypertrophy or vascular anomalies.

Results: We report five additional cases of TSC associated with vascular anomalies or overgrowth that contribute to our understanding of some of the pathways and treatments involved in vascular anomalies.

Conclusion: Hemihypertrophy and vascular anomalies may be more frequent in the setting of TSC than previously appreciated. A common pathogenetic mechanism may tie these manifestations together.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age Distribution
  • Comorbidity
  • Everolimus / therapeutic use
  • Female
  • Genetic Predisposition to Disease / epidemiology*
  • Humans
  • Incidence
  • Infant
  • Mutation
  • Prognosis
  • Risk Assessment
  • Sampling Studies
  • Severity of Illness Index
  • Sex Distribution
  • Sirolimus / therapeutic use
  • Treatment Outcome
  • Tuberous Sclerosis / diagnosis*
  • Tuberous Sclerosis / drug therapy
  • Tuberous Sclerosis / epidemiology*
  • Tuberous Sclerosis / genetics
  • Tuberous Sclerosis Complex 1 Protein
  • Tumor Suppressor Proteins / genetics*
  • Vascular Malformations / diagnosis*
  • Vascular Malformations / drug therapy
  • Vascular Malformations / epidemiology*
  • Vascular Malformations / genetics

Substances

  • Tuberous Sclerosis Complex 1 Protein
  • Tumor Suppressor Proteins
  • Everolimus
  • Sirolimus